相关实验视频
Updated: Jan 8, 2026

10:42
A Free-breathing fMRI Method to Study Human Olfactory Function
Published on: July 30, 2017
10.0K
嗅觉唤起EEG的复杂性作为阿尔茨海默病的基于证据的标志物
Justin Joseph1, V R Simi2, K M Rashmi1
1Department of Electronics and Communication Engineering, Manipal Institute of Technology Bengaluru, Manipal Academy of Higher Education, Manipal 576104, India.
Neuroscience
|December 22, 2025
概括
早期阿尔茨海默病 (AD) 检测使用可解释的人工智能框架进行改进,分析嗅觉事件相关潜力 (OERPs). 这种方法提高了识别嗅觉障碍的准确性,这是阿尔茨海默氏症早期关键症状.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 生物医学工程 生物医学工程
背景情况:
- 嗅觉障碍是已知的阿尔茨海默病 (AD) 的早期指标.
- 目前的神经成像技术,如fMRI和fNIRS,以及EEG特征,缺乏足够的灵敏度,用于基于嗅觉功能的早期AD检测.
- 需要更准确和更敏感的方法来检测AD的嗅觉功能障碍.
研究的目的:
- 开发和验证一个可解释的人工智能 (XAI) 框架,以更好地检测阿尔茨海默病中的嗅觉障碍.
- 用嗅觉事件相关潜能 (OERP) 的样本 (SE) 来评估拟议的XAI框架的有效性.
- 将XAI框架的性能与现有的机器学习和信号处理方法进行比较.
主要方法:
- 开发了一个XAI框架,结合了歧视性分析,天真贝叶斯和值分类器.
- 该框架使用从Fz/Pz电极记录的嗅觉事件相关潜能 (OERP) 计算的样本 (SE).
- 性能与使用各种OERP和神经成像特征的支持向量机,后勤回归,值和光梯度增强分类器进行了基准测试.
主要成果:
- 拟议的XAI框架在检测嗅觉障碍方面取得了92.14%的高精度.
- 这种准确性超过了传统方法,包括支向量机 (88.20%) 和后勤回归 (67.42%).
- 在AD患者中观察到SE减少,与OERP动态性降低和嗅觉刺激敏感性降低相关.
结论:
- 开发的XAI框架通过嗅觉事件相关潜力为早期阿尔茨海默病检测提供了更准确和更易于解释的方法.
- 对OERP的样本 Entropy分析提供了在AD中嗅觉功能障碍的敏感生物标志物.
- 这种方法有望改善阿尔茨海默病的早期诊断和干预策略.
更多相关视频
相关概念视频
Olfaction
48.0K
The sense of smell is achieved through the activities of the olfactory system. It starts when an airborne odorant enters the nasal cavity and reaches olfactory epithelium (OE). The OE is protected by a thin layer of mucus, which also serves the purpose of dissolving more complex compounds into simpler chemical odorants. The size of the OE and the density of sensory neurons varies among species; in humans, the OE is only about 9-10 cm2.
The olfactory receptors are embedded in the cilia of the...
The olfactory receptors are embedded in the cilia of the...
48.0K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K

